Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ORIC

Oric Pharmaceuticals Q3 2026 Earnings Date & Estimates

Oric Pharmaceuticals logo
$12.77 +1.18 (+10.18%)
Closing price 04:00 PM Eastern
Extended Trading
$12.74 -0.03 (-0.20%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oric Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Oric Pharmaceuticals in Q3 2026

Oric Pharmaceuticals is expected to post earnings of -$0.3838 per share. In the same quarter a year earlier Oric Pharmaceuticals reported -$0.33 per share. Oric Pharmaceuticals last reported on August 3, 2026, posting -$0.38 per share and missing the -$0.3594 consensus estimate. Oric Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3838
Prior-Year EPS
-$0.33

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.38 (Missed by -$0.0207)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Oric Pharmaceuticals Q3 2026 Earnings FAQ

Oric Pharmaceuticals (NASDAQ:ORIC) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Oric Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Oric Pharmaceuticals to post earnings of -$0.3838 per share for Q3 2026.

Oric Pharmaceuticals Earnings Headlines

Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-oric-oric-using-off-171212171.html
ORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
October 6, 2026  |  marketscreener.comM
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
October 15 at 1:00 AM  |  Weiss Ratings (Ad)
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374985/0/en/oric-pharmaceuticals-announces-agreement-with-cancer-research-uk-to-advance-a-potential-first-in-class-cip2a-targeted-therapy-into-clinical-development.html
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rated "Outperform" in New Coverage at Leerink Partners
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086938
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374038/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
See More Oric Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oric Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oric Pharmaceuticals and other key companies, straight to your email.

About Oric Pharmaceuticals

Oric Pharmaceuticals (NASDAQ:ORIC) (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research is centered on mechanisms that enable tumors to resist or evade treatment, with the goal of restoring sensitivity to established cancer therapies and improving patient outcomes.

Oric’s pipeline has included investigational small-molecule therapies designed to target cancer biology and treatment resistance. These programs include ORIC-533, an oral inhibitor of CD73 being studied in oncology, and ORIC-944, an oral allosteric inhibitor of EED, a component of the polycomb repressive complex 2. The company has also developed ORIC-114, a brain-penetrant investigational inhibitor directed at selected EGFR and HER2 alterations.

Founded in 2014 and headquartered in South San Francisco, California, Oric Pharmaceuticals conducts research and clinical development activities through collaborations with academic institutions, clinical investigators and other biotechnology or pharmaceutical organizations. Its programs are intended for patients with solid tumors and hematologic malignancies, although the availability and status of specific candidates may change as clinical studies progress.

View Oric Pharmaceuticals Profile
Earnings Tools